Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates ...

Analysis of AstraZeneca's market potential, including China and IRA impacts, and the importance of key readouts in 2025 for ...

SAN DIEGO, CA / ACCESSWIRE / January 9, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

AstraZeneca PLC (AZN) stock saw a modest uptick, ending the day at $67.01 which represents a slight increase of $0.43 or 0.65% from the prior close of $66.58. The stock opened at $67.19 and touched a ...

AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from Bank ...

This complaint was first surfaced by Law.com Radar, ALM's source for immediate alerting on just-filed cases in state and federal courts. Law.com Radar now offers state court coverage nationwide. Sign ...

As we enter 2025, many growth stocks are trading at high valuations and could be running out of room to rise in the near term ...

We recently compiled a list of the 10 Best FTSE Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

AstraZeneca PLC AZN shares inched down 0.41% to £106.68 Tuesday, on what proved to be an all-around rough trading session for ...